Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Magalashvili

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Journal of Neurology|July 12, 2023
Practical recommendations on treatment of multiple sclerosis with Cladribine: an Israeli Experts Group‏ ViewpointPanayiota Petrou, Anat Achiron, Esther Ganelin Cohen, et al.
BMC Neurology|April 18, 2015
A personalized, intense physical rehabilitation program improves walking in people with multiple sclerosis presenting with different levels of disability: a retrospective cohortAlon Kalron, Dalia Nitzani, David Magalashvili, et al.
Plos One|August 13, 2013
Modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional studyAnat Achiron, Joab Chapman, David Magalashvili, et al.
Journal of Neuroimmunology|October 16, 2021
Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional studyAnat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, et al.
Journal of the Neurological Sciences|December 7, 2021
Effect of natalizumab treatment on the rate of No Evidence of Disease Activity in young adults with multiple sclerosis in relation to pubertal stageShay Menascu, Aviva Fattal-Valevski, Adi Vaknin-Dembinsky, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 15, 2021
COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021Anat Achiron, Mark Dolev, Shay Menascu, et al.
Journal of the Neurological Sciences|January 29, 2022
COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster doseSapir Dreyer-Alster, Shay Menascu, Mathilda Mandel, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 25, 2026
Heterogeneous response to efgartigimod in real-world experience with myasthenia gravis: Predictors and treatment strategiesLior Fuchs, Ifat Vigiser, Hadar Kolb, et al.
Cell Reports. Medicine|May 5, 2021
Potential role of indolelactate and butyrate in multiple sclerosis revealed by integrated microbiome-metabolome analysisIzhak Levi, Michael Gurevich, Gal Perlman, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Journal of Neurology|July 12, 2023
Practical recommendations on treatment of multiple sclerosis with Cladribine: an Israeli Experts Group‏ ViewpointPanayiota Petrou, Anat Achiron, Esther Ganelin Cohen, et al.
BMC Neurology|April 18, 2015
A personalized, intense physical rehabilitation program improves walking in people with multiple sclerosis presenting with different levels of disability: a retrospective cohortAlon Kalron, Dalia Nitzani, David Magalashvili, et al.
Plos One|August 13, 2013
Modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional studyAnat Achiron, Joab Chapman, David Magalashvili, et al.
Journal of Neuroimmunology|October 16, 2021
Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional studyAnat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, et al.
Journal of the Neurological Sciences|December 7, 2021
Effect of natalizumab treatment on the rate of No Evidence of Disease Activity in young adults with multiple sclerosis in relation to pubertal stageShay Menascu, Aviva Fattal-Valevski, Adi Vaknin-Dembinsky, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 15, 2021
COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021Anat Achiron, Mark Dolev, Shay Menascu, et al.
Journal of the Neurological Sciences|January 29, 2022
COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster doseSapir Dreyer-Alster, Shay Menascu, Mathilda Mandel, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 25, 2026
Heterogeneous response to efgartigimod in real-world experience with myasthenia gravis: Predictors and treatment strategiesLior Fuchs, Ifat Vigiser, Hadar Kolb, et al.
Cell Reports. Medicine|May 5, 2021
Potential role of indolelactate and butyrate in multiple sclerosis revealed by integrated microbiome-metabolome analysisIzhak Levi, Michael Gurevich, Gal Perlman, et al.
Pageof 4